News | January 03, 2025
Veeda Group rebrands as Veeda Lifesciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Prithwish has close to 28 years of experience in a Commercial role
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Fiscal 2024 total sales for the joint venture were approximately $190 million
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Subscribe To Our Newsletter & Stay Updated
